ArticleSensors (Basel, Switzerland)2026
Toward Reliable Diabetic Retinopathy Screening.
Article in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Diabetic retinopathy (DR) grading requires reliable five-grade severity assessment under substantial acquisition variability and cross-dataset distribution shift. We propose PRISM-DR, a multi-objective five-grade DR grading framework trained under a gradient-partitioned strategy. The architecture is organized as a feedforward pipeline: a data-driven preprocessing stage followed by a ConvNeXtV2-Base backbone, a Recurrent BiFPN neck for multi-scale feature fusion, a Frequency-Aware Fusion module, a lightweight multi-scale reasoning transformer, dual classification heads with gradient-isolated pathways (categorical and ordinal), and a prototype memory module for embedding regularization. The CORAL ordinal head operates through a dedicated projection layer and is gradient-isolated from the backbone; the backbone is shaped by the cross-entropy, prototype contrastive, and view-consistency objectives, which carry indirect ordinal signal through severity-weighted class penalties and grade-indexed cluster regularization. The model is trained in a multi-crop setting with a phased loss curriculum designed for severely imbalanced DR datasets. Evaluated across six datasets under Fixed-Source, Multi-Target (FSMT) protocols, PRISM-DR trained on EyePACS + DDR achieves QWK of 0.835 on IDRiD, 0.865 on APTOS2019, and 0.720 on Messidor-2, with in-domain QWK = 0.920 and AUC-PR = 0.941 on EyePACS, outperforming RETFound, RETFound-Green, and MedGemma-4B in AUC-PR across all evaluated datasets. Quantitative interpretability evaluation against 755 expert-annotated lesion images yields 8.0× Energy Ratio Enrichment and a FAF gate retention ratio of 4.4× inside lesion regions, confirming that anatomically plausible spatial priors emerge from grade-level supervision alone, without pixel-level annotation. PRISM-DR establishes a superior accuracy-robustness-capacity trade-off for scalable, automated DR screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.